Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bigfoot Biomedical gets $37mm in Series B funding; closes round at $55mm

Executive Summary

Diabetes-focused device maker Bigfoot Biomedical Inc. raised $37mm in the first tranche of its Series B round co-led by first-time backer Janus Henderson Investors and returning shareholder Quadrant Capital Advisors, which were joined by other existing investors Cormorant Asset Management, Senvest Capital, Senvest Management, Visionnaire Ventures, JDRF T1D Fund, and T1D Exchange. The company will use the proceeds to continue developing its Class III devices including the Bigfoot Loop infusion pump-based closed loop automated insulin delivery system and Bigfoot Inject auto-titrating connected insulin pen-based system for diabetes patients receiving injection therapy.
Deal Industry
  • Biotechnology
  • Medical Devices
    • Monitoring Equipment & Devices
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies